For the twelve months ended Jun 30, 2026, Vistagen Therapeutics Inc. reported $2.50M of revenue and -$67.62M of net income.
VTGN revenue was $1.48M in fiscal Q1 2027 (ended Jun 30, 2026), up 504.9% from a year earlier and up 217.4% from the prior quarter. For the full fiscal 2026 it was $1.27M, up 161.1% from fiscal 2025. Compound annual growth was +3.1% over 5 years.
VTGN net income was -$13.03M in fiscal Q1 2027 (ended Jun 30, 2026), compared with -$15.10M a year earlier. For the full fiscal 2026 it was -$69.69M, compared with -$51.42M in fiscal 2025.
VTGN diluted EPS was -$0.30 in fiscal Q1 2027 (ended Jun 30, 2026), compared with -$0.47 a year earlier. For the full fiscal 2026 it was -$1.83, compared with -$1.67 in fiscal 2025.
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.27M | $486.0K | $1.06M | -$227.0K | $1.11M | $1.09M | $0 | - | $0 | $1.25M |
| Research and development | $54.97M | $39.38M | $20.02M | $44.38M | $35.41M | $11.93M | $13.37M | $17.10M | $7.76M | $5.20M |
| Selling, general and admin | $18.42M | $17.08M | $14.06M | $14.66M | $13.48M | $7.10M | $7.43M | $7.46M | $6.44M | $6.29M |
| Operating income | -$72.13M | -$55.97M | -$33.02M | -$59.27M | -$47.78M | -$17.93M | -$20.80M | -$24.56M | -$14.20M | -$10.25M |
| Interest expense | - | - | - | - | - | - | - | $8.0K | $8.9K | $4.6K |
| Pre-tax income | -$69.68M | -$51.41M | -$29.36M | -$59.24M | -$47.76M | -$17.93M | -$20.77M | -$24.59M | -$14.34M | -$10.25M |
| Income tax | $7.0K | $7.0K | $4.0K | $6.0K | $3.4K | $2.6K | $2.6K | $2.6K | $2.4K | $2.4K |
| Net income | -$69.69M | -$51.42M | -$29.36M | -$59.25M | -$47.76M | -$17.93M | -$20.77M | -$24.59M | -$14.35M | -$10.26M |
| EPS, basic | -$1.83 | -$1.67 | -$1.52 | -$8.51 | -$7.38 | -$0.49 | -$0.50 | -$0.90 | -$1.12 | -$1.54 |
| EPS, diluted | -$1.83 | -$1.67 | -$1.52 | -$8.51 | - | -$0.49 | -$0.50 | -$0.90 | -$1.12 | -$1.54 |
| Diluted shares | 38.1M | 30.9M | 19.4M | 7.0M | - | 86.1M | 43.9M | 28.6M | 13.9M | 7.5M |
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $30.79M | $67.13M | $119.17M | $16.64M | $68.14M | $103.11M | $1.36M | $13.10M | $10.38M | $2.92M |
| Current assets | $46.94M | $82.08M | $120.67M | $17.51M | $71.00M | $104.12M | $1.58M | $13.63M | $11.02M | $3.38M |
| Total assets | $48.56M | $84.34M | $123.65M | $21.09M | $74.64M | $108.28M | $5.77M | $14.01M | $11.28M | $3.71M |
| Current liabilities | $12.79M | $12.61M | $5.12M | $4.57M | $5.77M | $4.19M | $27.71M | $2.80M | $1.46M | $1.37M |
| Total debt | $96.0K | $0 | - | - | - | $0 | $56.5K | $57.3K | $53.9K | $54.8K |
| Total liabilities | $13.04M | $13.95M | $9.37M | $9.01M | $9.93M | $16.30M | $11.50M | $6.94M | $4.36M | $3.10M |
| Shareholders' equity | $35.52M | $70.39M | $114.29M | $12.08M | $64.72M | $91.98M | -$5.73M | $7.08M | $6.92M | $615.8K |
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$66.44M | -$42.10M | -$25.81M | -$49.72M | -$45.26M | -$12.07M | -$15.76M | -$14.53M | -$9.06M | -$7.26M |
| Capital expenditures | - | - | $0 | $528.0K | $0 | $275.4K | $0 | $174.0K | $1.6K | $239.1K |
| Free cash flow | - | - | -$25.81M | -$50.24M | -$45.26M | -$12.35M | -$15.76M | -$14.70M | -$9.06M | -$7.50M |
| Investing cash flow | -$877.0K | -$13.15M | -$61.0K | -$740.0K | -$200.4K | -$275.4K | $0 | -$174.0K | -$1.6K | -$239.1K |
| Financing cash flow | $30.97M | $3.21M | $128.40M | -$1.04M | $10.48M | $114.10M | $4.01M | $17.42M | $16.52M | $9.99M |
| Stock-based compensation | $4.00M | $4.32M | $2.18M | $3.34M | $3.48M | $2.31M | - | - | - | - |
| Depreciation and amortization | $199.0K | $150.0K | $127.0K | $130.0K | $153.5K | $117.6K | $103.1K | $91.2K | $80.7K | $54.9K |
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 161.1% | -54.3% | - | -120.5% | 1.8% | - | - | - | -100.0% | - |
| Operating margin | -5683.7% | -11517.1% | -3103.5% | - | -4308.3% | -1646.1% | - | - | - | -819.9% |
| Net margin | -5491.3% | -10579.8% | -2759.6% | - | -4306.8% | -1646.1% | - | - | - | -820.4% |
| Free cash flow margin | - | - | -2426.0% | - | -4080.8% | -1133.4% | - | - | - | -600.1% |
| Return on equity | -196.2% | -73.0% | -25.7% | -490.5% | -73.8% | -19.5% | - | -347.5% | -207.4% | -1665.4% |
| Return on assets | -143.5% | -61.0% | -23.7% | -280.9% | -64.0% | -16.6% | -359.9% | -175.5% | -127.2% | -276.3% |
| Current ratio | 3.67 | 6.51 | 23.55 | 3.83 | 12.32 | 24.85 | 0.06 | 4.87 | 7.56 | 2.47 |
| Debt to equity | 0.00 | 0.00 | - | - | - | 0.00 | - | 0.01 | 0.01 | 0.09 |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.48M | $465.0K | $303.0K | $258.0K | $244.0K | -$15.0K | $234.0K | $183.0K | $84.0K | $197.0K | $411.0K | $278.0K |
| Research and development | $10.91M | $13.06M | $14.22M | $15.91M | $11.68M | $10.21M | $11.30M | $10.21M | $7.65M | $7.44M | $4.54M | $3.85M |
| Selling, general and admin | $3.92M | $4.12M | $5.63M | $4.40M | $4.37M | $4.27M | $4.05M | $4.20M | $4.57M | $4.12M | $3.76M | $3.21M |
| Operating income | -$13.35M | -$16.72M | -$19.55M | -$20.05M | -$15.80M | -$14.49M | -$15.12M | -$14.23M | -$12.13M | -$11.36M | -$7.88M | -$6.78M |
| Pre-tax income | -$13.03M | -$16.27M | -$18.90M | -$19.42M | -$15.10M | -$13.63M | -$14.09M | -$12.95M | -$10.73M | -$9.52M | -$6.35M | -$6.59M |
| Income tax | $0 | $7.0K | $0 | $0 | $0 | $0 | $0 | $7.0K | $0 | $1.0K | $0 | $0 |
| Net income | -$13.03M | -$16.27M | -$18.90M | -$19.42M | -$15.10M | -$13.63M | -$14.09M | -$12.96M | -$10.73M | -$9.52M | -$6.35M | -$6.59M |
| EPS, basic | -$0.30 | - | -$0.45 | -$0.54 | -$0.47 | -$0.44 | -$0.46 | -$0.42 | -$0.35 | - | -$0.22 | -$0.66 |
| EPS, diluted | -$0.30 | - | -$0.45 | -$0.54 | -$0.47 | -$0.44 | -$0.46 | -$0.42 | -$0.35 | - | -$0.22 | -$0.66 |
| Diluted shares | 43.0M | - | 42.2M | 35.7M | 31.9M | - | 30.7M | 30.6M | 30.6M | - | 29.4M | 10.0M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $16.99M | $30.79M | $47.37M | $62.79M | $48.98M | $67.13M | $74.72M | $84.25M | $102.92M | $119.17M | $126.56M | $37.61M |
| Current assets | $34.31M | $46.94M | $63.24M | $78.93M | $66.72M | $82.08M | $89.94M | $99.95M | $110.84M | $120.67M | $128.11M | $39.08M |
| Total assets | $35.74M | $48.56M | $65.06M | $80.93M | $68.92M | $84.34M | $92.31M | $102.50M | $113.55M | $123.65M | $131.07M | $42.20M |
| Current liabilities | $11.19M | $12.79M | $13.53M | $13.64M | $11.15M | $12.61M | $9.62M | $7.52M | $6.24M | $5.12M | $4.16M | $2.91M |
| Total debt | - | $96.0K | - | - | - | $0 | - | - | - | - | - | - |
| Total liabilities | $11.26M | $13.04M | $14.14M | $14.59M | $12.16M | $13.95M | $11.19M | $9.52M | $8.74M | $9.37M | $7.78M | $6.55M |
| Shareholders' equity | $24.48M | $35.52M | $50.92M | $66.34M | $56.77M | $70.39M | $81.12M | $92.97M | $104.80M | $114.29M | $123.28M | $35.65M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.71M | -$16.20M | -$17.63M | -$13.76M | -$18.85M | -$10.06M | -$10.28M | -$10.89M | -$10.87M | -$6.99M | -$4.75M | -$6.19M |
| Investing cash flow | $0 | -$99.0K | $104.0K | -$94.0K | -$788.0K | $527.0K | -$422.0K | -$7.79M | -$5.47M | -$29.0K | -$32.0K | $0 |
| Financing cash flow | $909.0K | -$283.0K | $2.11M | $27.65M | $1.49M | $1.95M | $1.17M | $0 | $88.0K | -$380.0K | $93.73M | $34.18M |
| Stock-based compensation | $991.0K | $889.0K | $1.10M | $1.10M | $916.0K | $963.0K | $1.08M | $1.11M | $1.16M | $522.0K | $507.0K | $584.0K |
| Depreciation and amortization | $52.0K | $52.0K | $54.0K | $53.0K | $40.0K | $40.0K | $39.0K | $37.0K | $34.0K | $33.0K | $31.0K | $31.0K |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 504.9% | - | 29.5% | 41.0% | 190.5% | -107.6% | -43.1% | -34.2% | -52.5% | 11.9% | 128.3% | - |
| Operating margin | -904.3% | -3595.1% | -6450.8% | -7772.5% | -6477.0% | - | -6461.5% | -7774.3% | -14441.7% | -5766.0% | -1918.2% | -2438.8% |
| Net margin | -882.8% | -3499.8% | -6237.3% | -7526.0% | -6186.5% | - | -6020.9% | -7082.5% | -12777.4% | -4833.0% | -1545.0% | -2369.8% |
| Current ratio | 3.07 | 3.67 | 4.67 | 5.79 | 5.98 | 6.51 | 9.35 | 13.29 | 17.77 | 23.55 | 30.76 | 13.43 |
| Debt to equity | - | 0.00 | - | - | - | 0.00 | - | - | - | - | - | - |
Source: XBRL data Vistagen Therapeutics Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Feb 17, 2015.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| VTGN | $2.50M | +287.3% | -$67.62M | -2702.6% | $8.2M |
| RLMD | - | - | -$61.93M | - | $441.6M |
| AXSM | $865.27M | +54.2% | -$157.29M | -18.2% | $7.05B |
| CMPS | - | - | -$266.30M | - | $1.30B |
| NBIX | $3.70B | +38.0% | $702.50M | 19.0% | $17.09B |